Investors

Recent Releases

August 21, 2025

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

GAITHERSBURG, Md. , Aug. 21, 2025 (GLOBE NEWSWIRE) -- As opioid emergencies continue to be the leading cause of accidental death in the United States , 1 Emergent BioSolutions (NYSE: EBS) is teaming up with Voices for Awareness and Facing Fentanyl Now in honor of National Fentanyl Prevention and

August 6, 2025

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Second Quarter 2025 Total Revenues of $140.9 million , above Q2 guidance by $21 million Second Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior year Second Quarter 2025 Gross Margin % of 36% and Adjusted Gross

July 28, 2025

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovation GAITHERSBURG, Md. , July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article,